1. Articles in category: Announcement

    1-24 of 30 1 2 »
    1. YmAbs Raises $50 Million in Equity Financing

      NEW YORK--(BUSINESS WIRE)--Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that it has closed a private placement among HBM Healthcare Investments and its current shareholders, raising $50 million. YmAbs’ Founder, President and Head of Business Development and Strategy, Thomas Gad said, “We are very pleased to welcome HBM as a significant shareholder in YmAbs, together with our existing shareh

      Read Full Article
      Mentions: Immunotherapy
    2. Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to entrectinib for “treatment of NTRK fusion-positive solid tumors.” NTRK fusions are molecular alterations that occur in a broad variety of adult and pediatric solid tumor types. Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inh

      Read Full Article
      Mentions: Treatment ALK
    3. YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      "Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced positive top line results from a pivotal study of 131I-burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma. Results showed a 58 months average survival for the patients treated with 131I-burtomab in the study, compared to an average of 4.7 month and no long term survival or cure, for a contemporary cohort in the Central German Childhood Cancer Registry. After more than a decade of follow-up, data shows more than 40% overall long term survival indicating that the treated children have ...

      Read Full Article
    4. EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

      EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

      HEMEL HEMPSTEAD, England and VIENNA, March 27, 2017 /PRNewswire/ -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Agency's (EMA) Committee for Medicinal...

      Read Full Article
      Mentions: Treatment
    5. St. Baldrick's Foundation Announces the Childhood Cancer STAR Act was Approved by the House and Now Moves to the Senate

      St. Baldrick's Foundation Announces the Childhood Cancer STAR Act was Approved by the House and Now Moves to the Senate

      "The St. Baldrick's Foundation, the largest private funder of childhood cancer research grants, is excited to announce that the Childhood Cancer STAR (Survivorship, Treatment, Access and Research) Act has passed the House of Representatives and is now moving on to the Senate. The Childhood Cancer STAR Act is an important bipartisan legislation designed to advance pediatric cancer research and child-focused cancer treatments, while also improving childhood cancer surveillance, and providing enhanced resources for survivors and those impacted by kids' cancers."

      Read Full Article
      Mentions: Treatment
    6. Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma

      LEUVEN, Belgium, May 2, 2016 /PRNewswire/ --

      Oncurious NV, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric cancers, today announces it has initiated a Phase I/IIa study that will evaluate the safety and tolerability and...

      Read Full Article
      Mentions: NMTRC
    7. MabVax Therapeutics' Fully Human Antibody Approach to Cancer Therapeutics and Imaging Featured in Three Presentations at AACR Annual Meeting in New Orleans

      SAN DIEGO, April 18, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its fully human antibody approach to cancer therapeutics and imaging will be featured in three separate poster...

      Read Full Article
      Mentions: Antibody Imaging
    8. Oncologist at The Children's Hospital of Philadelphia Appointed by President Obama to National Cancer Advisory Board

      Oncologist at The Children's Hospital of Philadelphia Appointed by President Obama to National Cancer Advisory Board

      Peter C. Adamson, M.D., a pediatric oncologist and leading scientist at The Children's Hospital of (CHOP), and a professor of Pediatrics and Pharmacology at the Perelman School of Medicine at the , has been appointed by President Obama to the National Cancer Advisory Board (NCAB). Dr. Adamson is the only pediatric oncologist to currently serve on the NCAB, and will work to ensure the voices of the pediatric cancer community are heard by decision makers in the federal government.

      Read Full Article
      Mentions: COG
    9. Kids v Cancer Announces "The Advancing Hope Act" To Reauthorize The Pediatric Priority Review Voucher Program

      Kids v Cancer Announces "The Advancing Hope Act" To Reauthorize The Pediatric Priority Review Voucher Program

      "With this in mind, Kids v Cancer is working on the Kids' Innovative Drugs (KIDS) Initiative to enable kids with cancer to benefit from the almost 900 drugs in the adult cancer pipeline.  "We think one of the best ways to help kids with cancer is to ensure that they can be treated with the most promising drugs, even if those drugs are sometimes drugs developed for adult cancers but not yet approved for juvenile use, or drugs that were developed for adult cancers but abandoned and may work for children," said Goodman."

      Read Full Article
    10. CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer

      CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer

      "The FDA's decision to grant Orphan Drug designation for aldoxorubicin in these three new indications is a key milestone for the aldoxorubicin clinical development program and a clear reflection of the high unmet medical need for new treatments in these cancer types," said Steven A. Kriegsman, CytRx President and Chief Executive Officer.  "These designations are also a testament to the team's regulatory and development expertise and part of our core strategy to bring aldoxorubicin to patients worldwide as rapidly as possible.  We look forward to reporting top-line results from both our Phase 2 GBM trial and our Phase ...

      Read Full Article
      Mentions: Treatment
    11. BSD Announces the Opening of the Center for Treatment of Children with Hyperthermia and Chemotherapy at Charité UMS

      SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Charité Universitätsmedizin Berlin (Charité), Department of Pediatric Hematology and Oncology, in cooperation with the Charité Department of Radiation Oncology, has opened a center dedicated to the treatment of pediatric tumors using hyperthermia and chemotherapy. Prof. Angelika Eggert MD, Chair of the Department of Pediatric Hematology and Oncology as well as President of th

      Read Full Article
      Mentions: Treatment
    12. MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma

      MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma

      SAN DIEGOSept. 25, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma.  In the U.S., the designation carries significant incentives for the development of drugs to treat rare and difficult diseases.  The Company is preparing to commence a Phase 2 clinical trial with the vaccine in 2015. MabVax's neuroblastoma vaccine is a bivalent vaccine that elicits an antibody response targeting the ...

      Read Full Article
      Mentions: Vaccine MSKCC
    13. ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Technology Licensed from Caltech

      LOS ANGELES, Sept. 24, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that it has established a licensing agreement with the California Institute of Technology (Caltech) for exclusive rights to novel technology for the...

      Read Full Article
      Mentions: Immunotherapy
    14. Abcam Licenses Novel Ceefourin Inhibitors of Multidrug Resistance Protein 4 from Children’s Cancer Institute

      Abcam Licenses Novel Ceefourin Inhibitors of Multidrug Resistance Protein 4 from Children’s Cancer Institute

      19 Sep 2014

      Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development

      Sydney, Australia and Cambridge, UK, 19 September, 2014: Children’s Cancer Institute and Abcam plc, a global leader in the supply of innovative protein research tools and services, announced today that they have entered into an exclusive licence, supply and distribution agreement for multidrug resistance protein 4 (MRP4/ABCC4) inhibitors, Ceefourin™ 1 and Ceefourin™ 2, for research purposes.

      The first known selective inhibitors of MRP4, Ceefourin™ 1 and Ceefourin™ 2 are potent, chemically distinct compounds and are the first known selective inhibitors of ...

      Read Full Article
    15. The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment

      MANCHESTER, England, July 22, 2014 /PRNewswire/ -- Elekta (NSE:EKTAb) and Royal Philips (NYSE:PHG, AEX:PHIA) announced today that The Christie NHS Foundation Trust (Manchester, UK), a specialist cancer center, will join a consortium whose mission is to develop the clinical value of an...

      Read Full Article
    1-24 of 30 1 2 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles